List view / Grid view
18 November 2015 | By Victoria White
miR-124 hit multiple targets, reducing androgen receptor signalling and reviving the potency of advanced prostate cancer treatment Xtandi (enzalutamide)...
26 October 2015 | By Victoria White
The discovery could shed light on how prostate cancer spreads and provides a possible new target for the disease...
30 September 2015 | By Victoria White
APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer...
5 August 2015 | By Victoria White
Two research projects involving ADXS-PSA, which is being developed for prostate cancer, have been selected for 2015 Movember Foundation-PCF Challenge Awards...
21 May 2015 | By Victoria White
Almost 90% of men with advanced prostate cancer carry genetic mutations in their tumours that could be targeted by either existing or new cancer drugs...
